42754-69-8

Usage

Chemical structure

A pyrazolo-pyrimidine derivative with a phenyl group attached to the third position of the pyrazole ring

Uses

Commonly used in pharmaceutical research and drug development for its potential therapeutic applications

Properties

Investigated for its anti-cancer, anti-inflammatory, and anti-fungal properties

Potential

Shows promise as a potential lead compound for the development of new drugs targeting various biological pathways.

Upstream product

• 77287-34-4 formamide 
• 42754-61-0 5-amino-3-phenyl-1H-pyrazole-4-carbonitrile 
• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 98-80-6 phenylboronic acid 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 98-88-4 benzoyl chloride 
• 5515-36-6 α-cyano-β-hydroxycinnamonitrile 
• 111509-91-2 (α-morpholinobenzylidene)malononitrile 
• 2032-36-2 Thiobenzmorpholid 
• 42754-56-3 2-(methoxyphenylmethylene)malononitrile 
• 46177-21-3 2-benzoylmalononitrile 
• 31646-28-3 4-((methylthio)(phenyl)methylene) morpholinium iodide 

Downstream Products

• 130867-89-9 1-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethyl)-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 871672-02-5 4-amino-1-(5-deoxy-2,3-diacetoxy-β-D-ribofuranosyl)-3-phenylpyrazolo[3,4-d]pyrimidine 
• 131192-73-9 2-(4-Amino-3-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-propane-1,3-diol 
• 130867-99-1 Acetic acid 3-acetoxy-2-(4-amino-3-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-propyl ester 
• 131212-19-6 3-(4-Amino-3-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-propane-1,2-diol; hydrochloride 
• 1286278-45-2 C₁₄H₁₁N₅ 
• 1286278-57-6 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-chlorophenyl)ethanone 
• 1286278-58-7 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone 
• 1286278-59-8 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-p-tolylethanone 
• 1286278-60-1 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(thiophen-2-yl)ethanone 
• 1286278-61-2 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-phenylacetamide 
• 1286278-62-3 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-fluorophenyl)acetamide 
• 1286278-63-4 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-chlorophenyl)acetamide 
• 1286278-66-7 ethyl 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate 

Relevant academic research and scientific papers

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1 H-pyrazolo[3,4- d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3 H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3KδInhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Accumulated pieces of evidence have shown that PI3Kδplays a critical role in chronic obstructive pulmonary disease (COPD). Using a fragment-hybrid approach, we discovered a potent and selective PI3Kδinhibitor (S)-18. In the biochemical assay, (S)-18 inhibits PI3Kδ(IC50 = 14 nM) with high selectivity over other class I PI3Ks (56～83 fold). (S)-18 also achieves good selectivity over other protein kinases in the kinome (S-score (35) = 0.015). In the cell, (S)-18 selectively and potently inhibits the PI3Kδ-mediated phosphorylation of AKT T308 but not other class I PI3K-mediated signaling. Additionally, (S)-18 exhibits no apparent inhibitory effect on CYP isoforms except for a moderate effect on CYP2C9. Furthermore, it shows no apparent inhibitory activity against hERG (IC50 > 10 μM). In vivo, (S)-18 displays favorable PK properties for inhaled delivery and improves lung function in a rodent model of pulmonary inflammation. These results suggest that (S)-18 might be a new potential therapeutic candidate for COPD.

ATG7 INHIBITORS AND THE USES THEREOF

Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS

This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor signaling pathway kinases-mediated diseases; or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3 -ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROSI; MAPK pathway kinases selected from ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, and MEK7; and P13K/AKT/mTor pathway kinases: selected from mTor, P13K a, Ρ13Κ β, P13Kγ, and P13K δ.

1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D

Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular molecules. Phospholipase D is a target to modulate cancer-cell invasiveness. This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1. Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the molecules presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles. The data strongly indicate that these inhibitory molecules directly block enzyme/vesicle substrate binding. Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment. This study reports synthesis of a new class of PLD inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure. These molecules exhibited inhibition of human recombinant PLD activity (IC 50) in the low-nanomolar to low-micromolar range with monomeric substrate diC4PC and phospholipid vesicles and micelles. Preliminary activity studies using recombinant human PLDs in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicates inhibition in the mid- to low-nanomolar range for these potent inhibitory novel molecules in a physiological environment.

Pyrazolo[3,4-d]pyrimidine analogues: Synthesis, characterization and their in vitro antiamoebic activity

Pyrazolo[3,4-d]pyrimidine analogues were synthesized by treating 3-phenyl-1H-pyrazolo[3,4-d]pyrimidine-4-amine with different sulfonyl chlorides and triethylamine in dry dichloromethane. The structure of all the compounds was elucidated by spectral data a

Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities

A series of two classes of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates were synthesized using click chemistry approach. All compounds were evaluated for inhibition of Src kinase and human ovarian adenocarcinoma (SK-Ov-3), breast carcinoma (MDA-MB

Kinase antagonists

The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.

Inhibitor scaffolds as new allele specific kinase substrates

The elucidation of protein kinase signaling networks is challenging due to the large size of the protein kinase superfamily (>500 human kinases). Here we describe a new class of orthogonal triphosphate substrate analogues for the direct labeling of analog

Polarized Ethylenes. IV. Synthesis of Polarized Ethylenes Using Thioamides and Methyl Dithiocarboxylates and their Application to Syntheses of Pyrazoles, Pyrimidines, Pyrazolopyrimidines, and 5-Azacyclazines

Polarized ethylenes having both electron-donating (an amino or a methylthio group) and electron-accepting (cyano, carbamoyl, methyl ester) groups on the adjacent two olefinic carbon atoms were prepared by the condensation of S-alkylthioamidinium salts or